- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Financial Times News
- Eli Lilly weight-loss drug found to address sleep apnoea in trial
- The race to develop the next generation of weight-loss drugs
- Amazon hopes anti-obesity drug demand will boost pharmacy business
- The Lex Newsletter: Living in an Ozempic world
- Eli Lilly strikes drug dispensing deal with Amazon
- US regulator delays decision on Eli Lilly’s Alzheimer’s drug donanemab
- Eli Lilly races to boost capacity as it rolls out rival to Novo Nordisk weight-loss drug
- Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results
- Eli Lilly calls for scrutiny of rival Novo Nordisk’s deal to expand production of weight-loss drug
- Eli Lilly’s weight-loss drug set for UK launch ‘within weeks’
More ▼
Key statistics
On Monday, Eli Lilly and Co (0Q1G:LSE) closed at 540.00, 0.00% below its 52-week high of 540.00, set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 540.00 |
Average volume | -- |
---|---|
Shares outstanding | 950.77m |
Free float | 949.20m |
P/E (TTM) | 124.96 |
Market cap | 689.18bn USD |
EPS (TTM) | 5.80 USD |
Annual div (ADY) | 4.61 CHF |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Feb 14 2024 |
Div pay-date | Mar 08 2024 |
Data delayed at least 20 minutes, as of Nov 27 2023 15:18 GMT.
More ▼